Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients

• Published in: Osteoporosis international Vol. 34; no. 10; pp. 1783 - 1791
• Main Authors: Tsai, Yi-Lun, Wu, Chih-Hsing, Li, Chia-Chun, Shih, Chien-An, Chang, Yin-Fan, Hwang, Jawl-Shan, Tai, Ta-Wei
• Format: Journal Article
• Language: English
• Published: London Springer London 01.10.2023; Springer Nature B.V
• Subjects: Bone mineral density; Cardiovascular diseases; Endocrinology; Fractures; Hip; Hip joint; Medicine; Medicine & Public Health; Monoclonal antibodies; Mortality; Original Article; Orthopedics; Osteoporosis; Patient compliance; Patients; Population studies; Rheumatology; Surgery; Adherence; All-cause mortality risk; Denosumab; Treatment duration

Summary This study aimed to assess the impact of drug adherence and treatment duration for denosumab on mortality risk after hip fracture surgery. Lower all-cause mortality risk was associated with drug intervals of 7 months or less and longer treatment duration. The study highlights the importance...